Antiretroviral therapy and pre-exposure prophylaxis: Combined impact on HIV transmission and drug resistance in South Africa

Journal of Infectious Diseases

Volumn 208, Issue 2, 2013, Pages 224-234

  Abbas, Ume L ^a   Glaubius, Robert ^a   Mubayi, Anuj ^a   Hood, Gregory ^b   Mellors, John W ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PITTSBURGH SUPERCOMPUTING CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; ART; chemoprophylaxis; HIV drug resistance; HIV epidemic; HIV transmission; mathematical model; pre exposure prophylaxis; PrEP; South Africa

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRETROVIRAL THERAPY; ART; CHEMOPROPHYLAXIS; HIV DRUG RESISTANCE; HIV EPIDEMIC; HIV TRANSMISSION; MATHEMATICAL MODEL; PRE-EXPOSURE PROPHYLAXIS; PREP; SOUTH AFRICA;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SOUTH AFRICA; YOUNG ADULT;

EID: 84879325297     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit150     Document Type: Article

References (49)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, Geneva, Switzerland
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-22
6. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003) 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.
7. Wandel S, Egger M, Rangsin R, et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008; 84(Suppl 1):i31-6
8. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-9 (Pubitemid 40563350)
9. SACEMA. The modes of transmission of HIV in South Africa, UNAIDS: Geneva, Switzerland 2009
10. Department of Health South Africa. HIV and AIDS and STI Strategic Plan for South Africa, Pretoria. 2007-2011 2007
11. Department of Health South Africa. HIV and AIDS and STI Strategic Plan for South Africa, Pretoria. 2012-2016 2012
12. Mahy M, Lewden C, Brinkhof MW, et al. Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect 2010; 86(Suppl 2):ii28-34
13. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 2011; 56:e1-8
14. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012 2012
15. Wandeler G, Keiser O, Pfeiffer K, et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 2012; 59:e9-16
16. Department of Health South Africa. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa, Pretoria 2003
17. World Health Organization. HIV in the WHO African Region: progress towards achieving universal access to priority health sector interventions, Geneva, Switzerland: 2011 update. 2011
18. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a crosssectional study in Soweto, South Africa. AIDS 2010; 24:1679-87
19. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75:6410-7 (Pubitemid 32578160)
20. Harrison L, Castro H, Cane P, et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 2010; 24:1917-22
21. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS 2009; 23:1127-34
22. Kearney M, Maldarelli F, Shao W, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 2009; 83:2715-27
23. Little S. Transmission of HIV drug resistance and treatment response. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007
24. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-85
25. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66:1467-80
26. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother 2011; 66:2346-9
27. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral- naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-9
28. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307-17
29. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66
30. Deeks SG,Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIVinfected patients with detectable viremia. N Engl JMed 2001; 344:472-80 (Pubitemid 32164898)
31. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17
32. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203: 1174-81
33. Rehle TM, Hallett TB, Shisana O, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLOS One 2010; 5:e11094
34. Nowak MA, May R. Virus dynamics: mathematical principles of immunology and virology. New York: Oxford University Press, 2001
35. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505
36. Hofer E. Sensitivity analysis in the context of uncertainty analysis for computationally intensive models. Comput Phys Commun 1999; 117: 21-34
37. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24:915-9
38. Keiser O, Chi BH, Gsponer T, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 2011; 25:1761-9
39. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLOS ONE 2007; 2:e875
40. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14:52-8 (Pubitemid 24032682)
41. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57
42. UNAIDS. AIDS at 30: Nations at the crossroads 2011
43. Vital signs: HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-23
44. World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Geneva, WHO 2010
45. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLOS Med 2011; 8: e1001056
46. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-8
47. Hamers RL, Sigaloff KC,Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub- Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-9
48. Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007; 8:171-83
49. Wolpaw BJ, Mathews C, Chopra M, et al. The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field. BMC Health Serv Res 2010; 10:73.